FAST-funded researcher highlights the involvement of UBE3A in different neurodegenerative diseases
New research spotlights UBE3A as more than the gene behind Angelman syndrome—revealing how its role across brain cells could unlock insights for AS, autism, Alzheimer’s, and other neurological conditions.
Exciting Announcement: Launch of Our New Electronic Journal
FAST has launched FAST-DART, a new open-access journal built to share every Angelman syndrome research finding, including negative results, so no discovery is lost, and progress toward treatments can move faster.
Community Update: New Insights into Health and Prevention in Angelman Syndrome
A newly published study explores mortality risks in Angelman syndrome, highlighting key preventive areas like silent aspiration and pneumonia, while providing essential care resources for families.
The Economic Burden of Caring for Individuals with Angelman Syndrome
Angelman syndrome affects entire families: a new study estimates caregiving costs nearly $80,000 per household each year, underscoring the urgent need for stronger supports, services, and meaningful treatments.
FAST Poland Organized the 1st Polish National Angelman Syndrome Conference
FAST Poland hosted its first National Angelman Syndrome Conference for International Angelman Day, drawing 164 registered guests to explore clinical research, epilepsy, safety, and quality of life for AS families.
FAST Italy Hosts Its First Scientific Symposium on Angelman Syndrome
FAST Italy’s first-ever Scientific Symposium drew over 100 attendees and unveiled two new biotech companies, MavriX Bio and CourageAS Bio, advancing gene therapies for Angelman syndrome.
A high sensitivity assay of UBE3A ubiquitin ligase activity from Dr. Albert Keung’s Lab
A FAST-funded UBE3A activity assay from Dr. Albert Keung’s lab offers a faster, more sensitive tool for measuring and monitoring UBE3A function in Angelman syndrome research.
FAST-Affiliated Research Program at UCLA is awarded $5.8M to advance gene therapy for Angelman syndrome.
UCLA’s Dr. Roger Hollis received a $5.8 million CIRM award to advance a stem cell gene therapy for Angelman syndrome, moving the FAST-backed program closer to a Phase 1 trial.
Introducing the Innovation Seed Grant: Supporting Early-Stage Angelman Syndrome Research
FAST launches the Innovation Seed Grant, offering $10,000–$50,000 to help researchers gather early-stage data on bold, high-risk approaches to Angelman syndrome treatment.
FAST Spain Awards First Research Grant
FAST Spain awards its first research grant to study two novel biomarkers—the endocannabinoid system and transcriptomic profile—to better track Angelman syndrome progression and treatment.